CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The ideal regimen recommended by the guidelines for those with metastatic hormone-sensitive prostate cancer (mHSPC) is darolutamide, ADT, and docetaxel. The combination of ADT and androgen receptor pathway inhibition, which was the norm at the start of the ARASENS trial, has changed the therapeutic landscape for mHSPC; this analysis offers crucial information for choosing the right course of action for particular patients.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
